Lipanthyl Nt (Fenofibrate (Nanonised))

Fenofibrate, the active ingredient in Lipanthyl Nt, is a fibrate presented as a nanonised oral tablet for oral use. It lowers elevated triglyceride levels and improves lipid profiles in adults with dyslipidaemia. It is indicated for the management of hypertriglyceridaemia, mixed dyslipidaemia, and as adjunct therapy in primary hypercholesterolaemia, helping reduce cardiovascular risk in patients with abnormal lipid metabolism.

GNH USA supplies Lipanthyl Nt as a licensed, GDP‑compliant international pharmaceutical supplier, providing reliable bulk and parcel shipments to hospitals, pharmacies and clinics worldwide, with adherence to quality standards and regulatory requirements across EU and other markets.

Fenofibrate acts on lipid metabolism to treat various forms of dyslipidaemia. - Hypertriglyceridaemia: reduces serum triglyceride concentrations, lowering risk of pancreatitis. - Mixed dyslipidaemia: lowers triglycerides and LDL‑cholesterol while modestly raising HDL‑cholesterol. - Primary hypercholesterolaemia (adjunct): enhances the lipid‑lowering effect of statins by further decreasing LDL‑cholesterol.

Fenofibrate may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal discomfort: mild nausea, abdominal pain or dyspepsia. - Headache: transient mild to moderate headache episodes. - Elevated liver enzymes: temporary increase in hepatic transaminases. - Muscle cramps: occasional mild muscle soreness.

Serious or Rare Side Effects: - Myopathy or rhabdomyolysis: severe muscle pain with weakness and possible kidney injury. - Severe liver injury: jaundice, hepatitis or hepatic failure. - Acute renal failure: sudden decline in kidney function. - Allergic reactions: rash, pruritus or angio‑edema.

Before initiating fenofibrate therapy, clinicians should evaluate several clinical factors to ensure safe use. - Renal function: assess baseline creatinine clearance and monitor periodically. - Hepatic disease: avoid in active liver disease and monitor liver enzymes. - Pregnancy: use only if potential benefit justifies potential risk to the fetus. - Statin co‑therapy: limit high‑dose statin use to reduce myopathy risk. - Gout: monitor serum uric acid as fenofibrate may precipitate gout attacks. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Fenofibrate can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Gemfibrozil: combined use markedly increases risk of myopathy. - High‑dose statins (e.g., rosuvastatin >20 mg): heightened myopathy potential. - Cyclosporine: may raise fenofibrate plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: fenofibrate may enhance anticoagulant effect, requiring INR monitoring. - Antidiabetic agents: may affect glycemic control, adjust doses as needed. - Thiazide diuretics: can increase serum uric acid, risking gout flares.